Group 1 - The major shareholders of Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. are Yang Zongmeng and Wang Haibo, holding 7.18% and 5.41% of the total shares respectively before the reduction plan [1][2] - Yang Zongmeng planned to reduce his holdings by up to 4,270,800 shares, which is 0.41% of the total share capital, due to personal financial needs [1][2] - The reduction plan was disclosed on June 23, 2025, and the actual reduction took place from July 14 to July 16, 2025 [2][3] Group 2 - Yang Zongmeng reduced his holdings by 10,365,721 shares, representing 1.00% of the total share capital, with a total amount of approximately 92.79 million yuan [2][3] - Wang Haibo reduced his holdings by 4,270,722 shares, which is 0.41% of the total share capital, with a total amount of approximately 38.59 million yuan [3] - After the reductions, Yang Zongmeng's remaining shares are 64,009,773, which is 6.18% of the total share capital, while Wang Haibo's remaining shares are 51,828,605, which is 5.00% [3]
复旦张江: 复旦张江关于持股5%以上股东减持股份结果公告